指南与共识血管炎

2018年EULAR大血管炎管理建议更新

2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
指南 / 共识 · Ann Rheum Dis · 2019-07-03

该更新基于系统文献综述和13国20位专家意见,形成3条总体原则和10条建议,涵盖大血管炎的诊断确认、糖皮质激素诱导缓解、托珠单抗等辅助治疗及抗血小板药物使用调整。

要点

  • 疑似大血管炎需通过影像学或组织学确认诊断。
  • 活动性GCA或TAK应立即使用高剂量糖皮质激素诱导缓解。
  • 不再推荐常规使用抗血小板或抗凝治疗大血管炎。

核心结论

  • 更新建议旨在将当前科学证据和专家意见转化为更好的临床管理和改善患者结局。

研究设计与样本

  • 采用EULAR标准化操作流程,进行系统文献综述并征求来自13个国家的20位专家意见。

主要发现

  • 形成了3条总体原则和10条建议。
  • 推荐疑似大血管炎通过影像学或组织学确认诊断。
  • 活动性GCA或TAK应立即使用高剂量糖皮质激素(40-60 mg/天泼尼松等效)诱导缓解。
  • 推荐对特定GCA患者(难治性或复发性疾病、存在糖皮质激素相关不良事件或并发症风险增加)使用托珠单抗辅助治疗,甲氨蝶呤可作为替代。
  • 所有TAK患者应联合糖皮质激素使用非生物性糖皮质激素节约剂,难治性或复发性患者可使用生物制剂。

关键数值与推荐

  • 高剂量糖皮质激素 therapy 为40-60 mg/天泼尼松等效,用于活动性GCA或TAK的诱导缓解。
  • 托珠单抗用于特定GCA患者(难治性或复发性疾病、存在糖皮质激素相关不良事件或并发症风险增加)。
  • 甲氨蝶呤可作为托珠单抗的替代。
  • 不再推荐常规使用抗血小板或抗凝治疗大血管炎,除非有其他原因指示。

临床怎么用

  • 临床中应通过影像学或组织学确认大血管炎诊断。
  • 对活动性GCA或TAK立即启动高剂量糖皮质激素诱导缓解。
  • 对特定GCA患者考虑托珠单抗或甲氨蝶呤辅助治疗。
  • 所有TAK患者联合糖皮质激素使用非生物性糖皮质激素节约剂。
  • 避免常规使用抗血小板或抗凝治疗大血管炎,除非有其他指征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. METHODS: Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. RESULTS: Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. CONCLUSIONS: We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2019. PMID: 31270110. doi:10.1136/annrheumdis-2019-215672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。